CFGS
RARE icon

Concourse Financial Group Securities’s Ultragenyx Pharmaceutical RARE Stock Holding History

Concourse Financial Group Securities’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3
Closed -$153 – 2358
2024
Q2 		$123 Buy
+3
New +$128 ﹤0.01% 2265
2023
Q3 		– Sell
-13
Closed -$515 – 2396
2023
Q2 		$599 Buy
+13
New +$603 ﹤0.01% 2206

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Concourse Financial Group Securities's RARE Position: Q3 2024 in Review

Concourse Financial Group Securities sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2024, closing a stake of 3 shares — an estimated $153 sold.

Concourse Financial Group Securities first reported a position in RARE in Q2 2023 and held it in 2 quarters. The position peaked at $599 in Q2 2023. 301 funds tracked by Wall St. Rank hold RARE as of Q3 2024.

  • Concourse Financial Group Securities reported no remaining Ultragenyx Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Concourse Financial Group Securities sold 3 Ultragenyx Pharmaceutical shares in Q3 2024, an estimated $153.
  • Concourse Financial Group Securities first reported a position in Ultragenyx Pharmaceutical in Q2 2023 and held it in 2 quarters.
  • Concourse Financial Group Securities's Ultragenyx Pharmaceutical position peaked at $599 in Q2 2023.
  • 301 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2024.

Based on Concourse Financial Group Securities's 13F filing for Q3 2024, filed 10 Oct 2024.